Natalie Welch - Pacific Biosciences Chief Officer
| PACB Stock | USD 1.97 0.04 2.07% |
Insider
Natalie Welch is Chief Officer of Pacific Biosciences of
| Address | 1305 O?Brien Drive, Menlo Park, CA, United States, 94025 |
| Phone | 650 521 8000 |
| Web | https://www.pacb.com |
Pacific Biosciences Management Efficiency
The company has return on total asset (ROA) of (0.1061) % which means that it has lost $0.1061 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.648) %, meaning that it created substantial loss on money invested by shareholders. Pacific Biosciences' management efficiency ratios could be used to measure how well Pacific Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. As of December 21, 2024, Return On Tangible Assets is expected to decline to -0.39. In addition to that, Return On Capital Employed is expected to decline to -0.21. At present, Pacific Biosciences' Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 1.1 B, whereas Non Currrent Assets Other are forecasted to decline to about 3.7 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| Rex CFA | Anebulo Pharmaceuticals | 64 | |
| Kristina Masson | Acrivon Therapeutics, Common | 44 | |
| Kenneth JD | Century Therapeutics | N/A | |
| Benjamin Dake | Aerovate Therapeutics | 48 | |
| Yuichi MD | MediciNova | 74 | |
| Guizhong Liu | Adagene | 53 | |
| Andreas EMBA | Molecular Partners AG | 58 | |
| Man MBA | Adagene | 47 | |
| Luis Borges | Century Therapeutics | 62 | |
| Kenneth Cundy | Anebulo Pharmaceuticals | 65 | |
| Gregory Russotti | Century Therapeutics | 57 | |
| Thomas Schwerzmann | Molecular Partners AG | N/A | |
| Peter MD | Acrivon Therapeutics, Common | 61 | |
| Fatima MD | Shattuck Labs | N/A | |
| LLM JD | Rezolute | 63 | |
| , MBA | Molecular Partners AG | 51 | |
| Rasmus HolmJorgensen | Acrivon Therapeutics, Common | 52 | |
| MD MPH | MediciNova | 56 | |
| Eric Devroe | Acrivon Therapeutics, Common | 45 | |
| Jesper Olsen | Acrivon Therapeutics, Common | N/A | |
| Donna Dea | Aerovate Therapeutics | N/A | |
Management Performance
| Return On Equity | -0.65 | ||||
| Return On Asset | -0.11 |
Pacific Biosciences Leadership Team
Elected by the shareholders, the Pacific Biosciences' board of directors comprises two types of representatives: Pacific Biosciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Pacific. The board's role is to monitor Pacific Biosciences' management team and ensure that shareholders' interests are well served. Pacific Biosciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Pacific Biosciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Christian MBA, CEO, President | ||
| Brett JD, General Secretary | ||
| Stephen Turner, CoFounder CTO | ||
| Susan Kim, Chief Officer | ||
| Jeff Eidel, Chief Officer | ||
| Denis Zaccarin, Senior Development | ||
| Michele CPA, VP Officer | ||
| Jonas Korlach, Chief Officer | ||
| Mike Goloubef, Senior Quality | ||
| Trevin Rard, Head Relations | ||
| Mark Oene, Chief Officer | ||
| Natalie Welch, Chief Officer |
Pacific Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Pacific Biosciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.65 | ||||
| Return On Asset | -0.11 | ||||
| Profit Margin | (2.28) % | ||||
| Operating Margin | (1.40) % | ||||
| Current Valuation | 1.03 B | ||||
| Shares Outstanding | 294.32 M | ||||
| Shares Owned By Insiders | 9.32 % | ||||
| Shares Owned By Institutions | 84.52 % | ||||
| Number Of Shares Shorted | 54.38 M | ||||
| Price To Earning | 197.88 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Pacific Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Pacific Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Pacific Biosciences Of Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Pacific Biosciences Of Stock:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pacific Biosciences of. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pacific Biosciences. If investors know Pacific will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pacific Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.46) | Revenue Per Share 0.64 | Quarterly Revenue Growth (0.28) | Return On Assets (0.11) | Return On Equity (0.65) |
The market value of Pacific Biosciences is measured differently than its book value, which is the value of Pacific that is recorded on the company's balance sheet. Investors also form their own opinion of Pacific Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Pacific Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pacific Biosciences' market value can be influenced by many factors that don't directly affect Pacific Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Pacific Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Pacific Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pacific Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.